Beam Therapeutics's book value per share for the quarter that ended in Mar. 2026 was MXN204.38.
During the past 12 months, Beam Therapeutics's average Book Value Per Share Growth Rate was 1.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Beam Therapeutics was 41.00% per year. The lowest was -10.10% per year. And the median was 5.80% per year.
Beam Therapeutics's current price is MXN655.00. Its book value per share for the quarter that ended in Mar. 2026 was MXN204.38. Hence, today's PB Ratio of Beam Therapeutics is 3.20.
During the past 9 years, the highest P/B Ratio of Beam Therapeutics was 7.44. The lowest was 1.37. And the median was 2.84.
Warning Sign:
Beam Therapeutics Inc stock PB Ratio (=2.88) is close to 1-year high of 3.07.
Beam Therapeutics (MEX:BEAM) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Beam Therapeutics Book Value per Share Related Terms
Beam Therapeutics Book Value per Share Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BEAM vs ELVN, IDYA, PBLS: Book Value per Share Comparison
For the Biotechnology subindustry, Beam Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of MXN204.38 mean?
Beam Therapeutics (MEX:BEAM) has a Book Value per Share of MXN204.38 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Book Value per Share too high?
Beam Therapeutics' current Book Value per Share is MXN204.38. Overall, Beam Therapeutics has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Book Value per Share compare to ELVN and IDYA?
Beam Therapeutics' Book Value per Share of MXN204.38 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Book Value per Share is MXN204.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN571.91, compared to a current price of MXN655.00 — trading 14.5% above its estimated fair value. The current Book Value per Share is MXN204.38. Beam Therapeutics' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Book Value per Share is MXN204.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN655.00 is trading 14.5% above its estimated GF Value™ of MXN571.91.
GuruFocus considers Beam Therapeutics to be Fairly Valued.
Key valuation signals for MEX:BEAM:
Book Value per Share: MXN204.38
GF Value™: MXN571.91 vs. price of MXN655.00 (14.5% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
69GF Score
Get the complete analysis for MEX:BEAM
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
